IL-4 Inhibits the Expression of High Affinity IL-2 Receptors on Monoclonal Human B Cells
Overview
Affiliations
In the presence of anti-mu antibodies (anti-microAb), monoclonal B lymphocytes from patients suffering from B type chronic lymphocytic leukemia (B-CLL) can respond to IL-2. In contrast to the effect it exerts on normal B cells, IL-4 does not promote DNA synthesis by B-CLL lymphocytes. Rather this interleukin inhibits the response to IL-2 in all patients' cells that responded to this interleukin. We thus examined whether IL-4 would modulate the number and/or the affinity of IL-2 receptors. A 3-day activation of cells by anti-microAb induced a few hundred high affinity IL-2 receptors (HA-IL-2R) on B-CLL cell surface, as determined by Scatchard analysis. Treatment of cells with IL-4 caused a marked decrease in the number of HA-IL-2R without interfering with the binding ability of IL-2. In contrast with this profound suppressive effect, IL-4 did not down-regulate the expression of each chain, alpha and beta (p55 and p75, respectively), of the HA-IL-2R heterodimer. In fact, the expression of alpha and beta induced by anti-microAb was enhanced by IL-4. Altogether, IL-4 exerts a critical influence on the function and the configuration of HA-IL-2R without inhibiting the expression of two subunits, alpha and beta.
Damjanovich S, Bene L, Matko J, Alileche A, Goldman C, Sharrow S Proc Natl Acad Sci U S A. 1997; 94(24):13134-9.
PMID: 9371812 PMC: 24275. DOI: 10.1073/pnas.94.24.13134.
Morel B, Burke M, Kalagnanam J, McCarthy S, Tweardy D, Morel P Bull Math Biol. 1996; 58(3):569-94.
PMID: 8688839 DOI: 10.1007/BF02460597.
Fluckiger A, Garrone P, Durand I, Galizzi J, Banchereau J J Exp Med. 1993; 178(5):1473-81.
PMID: 8228801 PMC: 2191252. DOI: 10.1084/jem.178.5.1473.
Cytokines in the pathophysiology and treatment of chronic B-cell malignancies. A review.
Schuler M, Huber C, Peschel C Ann Hematol. 1995; 71(2):57-63.
PMID: 7654854 DOI: 10.1007/BF01699247.
Mainou-Fowler T, Copplestone J, Prentice A J Clin Pathol. 1995; 48(5):482-7.
PMID: 7629299 PMC: 502630. DOI: 10.1136/jcp.48.5.482.